Trial Outcomes & Findings for The ConnectedCancerCare Pilot Study (CCC) (NCT NCT03618017)

NCT ID: NCT03618017

Last Updated: 2020-11-04

Results Overview

We anticipate a response rate of 80% enrollment (n=60). We will assess the number of patients successfully recruited who enroll and complete the baseline survey.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

66 participants

Primary outcome timeframe

At baseline survey

Results posted on

2020-11-04

Participant Flow

160 eligible women were invited to participate; 66 women enrolled (completed the baseline survey and were randomized).

Participant milestones

Participant milestones
Measure
Control: Static Care Plan
The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as "standard of care."
Intervention: CCC Website
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Overall Study
STARTED
33
33
Overall Study
COMPLETED
26
28
Overall Study
NOT COMPLETED
7
5

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

11 participants did not self-report this data.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Static Care Plan
n=33 Participants
The control arm will receive a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as "standard of care."
CCC Website
n=33 Participants
ConnectedCancerCare (CCC) is a web- based guide to support survivorship care for women who have been treated for early- stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Total
n=66 Participants
Total of all reporting groups
Breast Cancer Stage at Diagnosis
Stage 0
3 Participants
n=31 Participants • 11 participants did not self-report this data.
2 Participants
n=24 Participants • 11 participants did not self-report this data.
5 Participants
n=55 Participants • 11 participants did not self-report this data.
Breast Cancer Stage at Diagnosis
Stage 1
14 Participants
n=31 Participants • 11 participants did not self-report this data.
15 Participants
n=24 Participants • 11 participants did not self-report this data.
29 Participants
n=55 Participants • 11 participants did not self-report this data.
Age, Continuous
54.1 years
STANDARD_DEVIATION 11.4 • n=33 Participants
57.8 years
STANDARD_DEVIATION 10.8 • n=33 Participants
56.0 years
STANDARD_DEVIATION 11.2 • n=66 Participants
Sex: Female, Male
Female
33 Participants
n=33 Participants
33 Participants
n=33 Participants
66 Participants
n=66 Participants
Sex: Female, Male
Male
0 Participants
n=33 Participants
0 Participants
n=33 Participants
0 Participants
n=66 Participants
Race/Ethnicity, Customized
White
27 Participants
n=33 Participants
29 Participants
n=33 Participants
56 Participants
n=66 Participants
Race/Ethnicity, Customized
Black
1 Participants
n=33 Participants
1 Participants
n=33 Participants
2 Participants
n=66 Participants
Race/Ethnicity, Customized
Hispanic
1 Participants
n=33 Participants
1 Participants
n=33 Participants
2 Participants
n=66 Participants
Race/Ethnicity, Customized
Asian
3 Participants
n=33 Participants
1 Participants
n=33 Participants
4 Participants
n=66 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=33 Participants
1 Participants
n=33 Participants
2 Participants
n=66 Participants
Education
High school/some college
10 Participants
n=33 Participants
13 Participants
n=33 Participants
23 Participants
n=66 Participants
Education
College graduate or more
23 Participants
n=33 Participants
20 Participants
n=33 Participants
43 Participants
n=66 Participants
Insurance
Medicare
10 Participants
n=33 Participants
8 Participants
n=33 Participants
18 Participants
n=66 Participants
Insurance
Medicaid/Other government
3 Participants
n=33 Participants
1 Participants
n=33 Participants
4 Participants
n=66 Participants
Insurance
Private
20 Participants
n=33 Participants
24 Participants
n=33 Participants
44 Participants
n=66 Participants
Employment
Employed
17 Participants
n=33 Participants
17 Participants
n=33 Participants
34 Participants
n=66 Participants
Employment
Retired
10 Participants
n=33 Participants
8 Participants
n=33 Participants
18 Participants
n=66 Participants
Employment
Other not employed
6 Participants
n=33 Participants
8 Participants
n=33 Participants
14 Participants
n=66 Participants
Breast Cancer Stage at Diagnosis
Stage 2
14 Participants
n=31 Participants • 11 participants did not self-report this data.
7 Participants
n=24 Participants • 11 participants did not self-report this data.
21 Participants
n=55 Participants • 11 participants did not self-report this data.
Primary Surgical Treatment
Lumpectomy
20 Participants
n=33 Participants
17 Participants
n=33 Participants
37 Participants
n=66 Participants
Primary Surgical Treatment
Unilateral mastectomy
5 Participants
n=33 Participants
10 Participants
n=33 Participants
15 Participants
n=66 Participants
Primary Surgical Treatment
Bilateral mastectomy
8 Participants
n=33 Participants
6 Participants
n=33 Participants
14 Participants
n=66 Participants
Received radiation
No
9 Participants
n=33 Participants
11 Participants
n=33 Participants
20 Participants
n=66 Participants
Received radiation
Yes
24 Participants
n=33 Participants
22 Participants
n=33 Participants
46 Participants
n=66 Participants
Received Chemotherapy
No
17 Participants
n=33 Participants
19 Participants
n=33 Participants
36 Participants
n=66 Participants
Received Chemotherapy
Yes
16 Participants
n=33 Participants
14 Participants
n=33 Participants
30 Participants
n=66 Participants
On endocrine therapy
No
7 Participants
n=33 Participants
2 Participants
n=33 Participants
9 Participants
n=66 Participants
On endocrine therapy
Yes
26 Participants
n=33 Participants
31 Participants
n=33 Participants
57 Participants
n=66 Participants
Number of Comorbidities
0
15 Participants
n=33 Participants
15 Participants
n=33 Participants
30 Participants
n=66 Participants
Number of Comorbidities
1
14 Participants
n=33 Participants
12 Participants
n=33 Participants
26 Participants
n=66 Participants
Number of Comorbidities
2+
4 Participants
n=33 Participants
6 Participants
n=33 Participants
10 Participants
n=66 Participants
Had a primary care provider at enrollment
No
2 Participants
n=33 Participants
2 Participants
n=33 Participants
4 Participants
n=66 Participants
Had a primary care provider at enrollment
Yes
31 Participants
n=33 Participants
31 Participants
n=33 Participants
62 Participants
n=66 Participants

PRIMARY outcome

Timeframe: At baseline survey

Population: Number of eligible women invited to participate

We anticipate a response rate of 80% enrollment (n=60). We will assess the number of patients successfully recruited who enroll and complete the baseline survey.

Outcome measures

Outcome measures
Measure
Recruitment Population
n=160 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Number of Breast Cancer Patients Successfully Recruited to Participate in the Study
66 Participants

SECONDARY outcome

Timeframe: Follow-Up Survey: 3 months

Population: Intervention arm only; participants who completed the follow-up survey at 3 months post-randomization

Acceptability and usability assessed by the following 6 key factors: 1. Ease of use; 2. Helpful during the transition to survivorship; 3. Helpful in terms of planning when to see my PCP and when to see my Oncologist; 4."Would recommend CCC to other patients"; 5. Length of time it took to go through the website; 6. Amount of information on the website. Each of the 6 factors will be assessed using a 5-point (1-5) Likert scale with higher scores (3, 4, 5) representing better acceptance and usability of the CCC website. Based on prior work, a cut off of 50% or more reporting a score of 3 or higher will be used to measure acceptance within each domain. The average of each participant's responses to the 6 items will result in one score per participant, on a scale of 1 - 5. A single summary score of acceptability across all participants will be determined by averaging the individual scores. On a scale of 1-5, a score of 3 or higher indicates acceptability to the majority of participants.

Outcome measures

Outcome measures
Measure
Recruitment Population
n=28 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Rating the Experience With the CCC Web-based, Survivorship Care Plan
4.4 score on a scale
Standard Deviation 2.0

SECONDARY outcome

Timeframe: 3 months

An 8 item list of continuing care services adapted from the CanSORT Provider Roles Scale (iCanCare Study) is used to assess participants' preferences for seeing their Oncologist or PCP.

Outcome measures

Outcome measures
Measure
Recruitment Population
n=26 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
n=28 Participants
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Screening for second primary cancers
5 Participants
14 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Surveillance (mammogram)
0 Participants
3 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
General preventive care
23 Participants
25 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Comorbidity management
24 Participants
24 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Physical effects
2 Participants
3 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Psychological effects
15 Participants
20 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Reassurance about recurrence risk
1 Participants
1 Participants
Percentage of Patients Reporting a Preference for an Oncologist vs. PCP for Their Continuing Cancer Care Services
Endocrine therapy management
13 Participants
15 Participants

SECONDARY outcome

Timeframe: 3 months

The percentage of patients who have scheduled a follow-up visit with their PCP after viewing the CCC web tool (intervention arm) or after receiving the static survivorship care plan (control arm).

Outcome measures

Outcome measures
Measure
Recruitment Population
n=26 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
n=28 Participants
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Percentage of Patients Scheduling a Primary Care Physician (PCP) Appointment
11 Participants
18 Participants

SECONDARY outcome

Timeframe: 3 months

A 5-point scale will be used to ask patients to rate their satisfaction with the coordination of care provided by their Oncologist and PCP. The rating scale will range from a value of 1 ('not at all') to a value of 5 ('extremely satisfied'), with a higher numeric value representing greater satisfaction with coordination of care. The mean satisfaction scores will be compared between the intervention and control arms.

Outcome measures

Outcome measures
Measure
Recruitment Population
n=26 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
n=28 Participants
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Patient-Reported Satisfaction With Oncologist/PCP Coordination of Care
3.1 score on a scale
Standard Deviation 1.2
3.7 score on a scale
Standard Deviation 1.0

SECONDARY outcome

Timeframe: 3 months

Population: Participants who saw a PCP after completing the baseline survey are included in the analysis population

Communication with PCP about provider roles was measured using an item adapted to the patient perspective from a prior study of providers' views about shared cancer care roles. Patients were asked if they communicated in the past 3 months with their PCP about who will manage specific aspects of their survivorship care (yes/no).

Outcome measures

Outcome measures
Measure
Recruitment Population
n=11 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
n=18 Participants
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Percentage of Patients That Communicated With PCP About Provider Roles
2 Participants
12 Participants

SECONDARY outcome

Timeframe: 3 months

Knowledge about team-based survivorship care was measured utilizing an 8-item scale adapted from the Perceived Primary Care Delivery of Survivorship Care Scale. It includes items specific to patients' knowledge of PCPs roles in team-based care delivery, (e.g. second cancer screening, symptom management). The responses were rated on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The responses to the 8 items were then averaged to create a mean knowledge summary score for each participant, ranging from 1 to 5, with higher values representing greater knowledge about team-based survivorship care.

Outcome measures

Outcome measures
Measure
Recruitment Population
n=26 Participants
Pre-randomization recruitment and enrollment
Intervention: CCC Website
n=28 Participants
ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Knowledge About Team-based Survivorship Care
3.4 score on a scale
Standard Deviation 0.9
3.7 score on a scale
Standard Deviation 0.6

Adverse Events

Control: Static Care Plan

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Intervention: CCC Website

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Lauren Wallner, Ph.D.

University of Michigan Rogel Cancer Center

Phone: 734-232-0788

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place